Spatial Repellents for Arbovirus Control (NCT03553277) | Clinical Trial Compass
CompletedNot Applicable
Spatial Repellents for Arbovirus Control
Peru18,240 participantsStarted 2015-06
Plain-language summary
Dengue viruses are the most medically important arthropod-borne pathogens worldwide, with transmission occurring in most tropical and sub-tropical regions. An estimated 390 million infections occur yearly. Although, there are considerable ongoing efforts to develop a vaccine, vector control remains the only option for reducing dengue virus (DENV) transmission and disease burden. The recent emergence of Aedes-borne Zika (ZIKV) and Chikungunya viruses (CHIKV) highlight need for novel vector control tools. The goal of this project is to determine the efficacy of a spatial repellent (SR) product (active ingredient transfluthrin) for reducing contact between household residents and vector mosquitos and as a result reduce DENV, ZIKV, and/or other Aedes-borne virus transmission. Henceforth the investigators will designate the combined risk of Aedes-borne dengue, Chikungunya, Zika virus transmission by (DCZV). Spatial repellency is used here as a general term to refer to a range of insect behaviors caused by airborne chemicals that reduce contact between people and disease vectors. This can include movement away from a chemical stimulus, and interference with host detection (attraction-inhibition) and/or feeding response.
Who can participate
Age range
2 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
LONGITUDINAL SEROCONVERSION Individual Level
Inclusion Criteria:
* ≥ 2 years of age
* plans to stay in study area for minimum of 12 months
* resident of household or frequent visitor (\~20% of day hours in house/mo)
Exclusion Criteria:
* \< 2 years of age
* temporary visitor to household
* plans to leave study area within next 12 months
FEBRILE SURVEILLANCE Household Level
Inclusion Criteria:
* adult head of households agree to health visits and census
* individuals spend a minimum of 4hrs per week during the daytime hours or sleep in the house. Temporary residents can be included.
Exclusion Criteria:
* households where study personnel identify a security risk (i.e., site where drugs are sold, residents are always drunk or hostile)
* sites where no residents spend time during the day (i.e., work 7d a week outside the home)
FEBRILE SURVEILLANCE Individual Level
Inclusion Criteria:
* individual who spends a minimum of 4 hours per week within the household
* ≥ 2 years of age
* fever at the time of presentation or report of feverishness within the previous 24 hours or presenting with a rash, arthralgia, arthritis or non-purulent conjunctivitis (suspicion of Zika determined by project physician)
Exclusion Criteria:
* \<2 years of age
* individuals who have spent less than 4 hours in the household during the week prior to illness
ENTOMOLOGICAL MONITORING Household Level
Inclusion Criteria:
\* adult head of households agrees to survey
Exclusion Criteria:
\* proper…
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.